CAS 51803-78-2 Nimesulide - Analytical Products / Alfa Chemistry

CAT	APS51803782
CAS	51803-78-2
Structure
Synonyms	N-(4-Nitro-2-phenoxyphenyl)methanesulfonamide, Nimulid, 2-Phenoxy-4-nitromethanesulfonanilide, Aulin, 4-Nitro-2-phenoxymethanesulfonanilide, Nimepast, Sulidene,Nimesulide, Mesulid, 4'-Nitro-2'-phenoxymethanesulfonanilide, Flogovital, Orthobid, Nisulid, Nimed
IUPAC Name	N-(4-nitro-2-phenoxyphenyl)methanesulfonamide
Molecular Weight	308.31
Molecular Formula	C13H12N2O5S
Canonical SMILES	CS(=O)(=O)Nc1ccc(cc1Oc2ccccc2)[N+](=O)[O-]
InChI	InChI=1S/C13H12N2O5S/c1-21(18,19)14-12-8-7-10(15(16)17)9-13(12)20-11-5-3-2-4-6-11/h2-9,14H,1H3

Accurate Mass	308.0467
Format	Neat

* Products or Services Interested: Nimesulide (51803-78-2)
* Your question
* Name
* Email
Verification Code

CAT	Size	Shipping	Storage Conditions	Description	Price
APS51803782-1	250MG	+20°C	+20°C	Subcategory: Pharmaceutical and veterinary compounds and metabolites	Inquiry
APS51803782-2	100MG	Room Temperature	2-8°C Fridge/Coldroom	Subcategory: European Pharmacopoeia (Ph. Eur.); API Family: Matrix - API Family See respective official monograph(s); Product Type: API	Inquiry
APS51803782-3	250MG	Room Temperature	+5°C	Subcategory: Non-steroidal anti-inflammatory drugs (NSAIDs), Mikromol, API standards, Analgesics; API Family: Matrix - API Family Nimesulide; Product Type: API	Inquiry

Case Study

Nimesulide Used for the Preparation of Dual-Drug Loaded Halloysite-PSBMA Hydrogels for Controlled Anti-Inflammatory Drug Delivery

Taktak, Fulya, and Ayşe Pınar Turgut Yiğen. Journal of Molecular Structure 1252 (2022): 132133.

Nimesulide (NIMS), a non-steroidal anti-inflammatory drug (NSAID), has been successfully employed in the preparation of a dual-drug delivery hydrogel system for rheumatoid arthritis treatment. In this study, NIMS was co-encapsulated with sulfasalazine (SLZ), a disease-modifying anti-rheumatic drug (DMARD), into acid-etched halloysite nanotubes (eHal) to enhance drug loading. The inner lumen volume of eHal was increased via acid treatment, enabling simultaneous loading of NIMS and SLZ from alkaline solutions under stirring for 24 h. Drug loading efficiency was quantified using UV spectroscopy at 393 nm for NIMS.
The drug-loaded eHal conjugates were then incorporated into a zwitterionic polymer matrix-poly[2-(methacryloyloxy)ethyl] dimethyl-(3-sulfopropyl) ammonium hydroxide (PSBMA)-via free radical polymerization. Both single- and dual-drug loaded PSBMA hydrogels were synthesized, with the dual system showing distinct release kinetics compared to individual formulations. Release was pH-dependent, with slower drug diffusion observed in acidic media due to reduced solubility.
Importantly, the resulting NIMS-containing PSBMA hydrogel demonstrated no cytotoxicity in in vitro assays, confirming its biocompatibility for sustained therapeutic applications.
This study illustrates that nimesulide is used for the preparation of dual-drug loaded hydrogel composites, offering a tunable and non-toxic platform for controlled delivery of anti-inflammatory agents in complex disease conditions such as rheumatoid arthritis.

Nimesulide Used for the Preparation of PLA-Based Microspheres for Sustained Drug Release Applications

Freitas, M. N., & Marchetti, J. M. (2005). International journal of pharmaceutics, 295(1-2), 201-211.

Nimesulide, a non-steroidal anti-inflammatory drug (NSAID), was effectively incorporated into polylactic acid (PLA-l) microspheres to develop a biodegradable, sustained-release delivery system. The microspheres were prepared using the classical emulsion solvent-evaporation technique. In this process, varying concentrations of PLA-l were dissolved in chloroform and emulsified into polyvinyl alcohol (PVA) aqueous solutions under high-speed stirring (11,000 rpm) with subsequent solvent evaporation.
Particle size analysis revealed a marked difference between unloaded and drug-loaded systems, with diameters of approximately 42.9 nm and 2.1 µm, respectively. Scanning electron microscopy confirmed the spherical morphology of the microspheres. Nimesulide was introduced into the optimized formulation at 7.5 mg per batch, yielding a high encapsulation efficiency of 70%.
In vitro drug release studies demonstrated a slow and controlled release profile, with only 28.7% of the drug released over 108 hours, confirming the system's potential for long-term anti-inflammatory therapy. The combination of PLA-l's biodegradability and PVA's surfactant properties proved essential for controlling particle formation and drug dispersion.

Nimesulide is Used for the Preparation of Chiral Mesoporous Silica Nanoparticle Drug Delivery Systems

Guo, Yingyu, et al. Microporous and Mesoporous Materials 294 (2020): 109862.

Nimesulide (NMS), a selective COX-2 inhibitor, was employed as a model drug to evaluate the performance of chiral-functionalized mesoporous silica nanoparticles (F-MSNs) in advanced drug delivery applications. In this study, levorotatory and dextrorotatory mesoporous silica nanoparticles, designated as FL-MSNs and FD-MSNs respectively, were synthesized to investigate chirality-dependent delivery behavior.
NMS was loaded into FL-MSNs and FD-MSNs by adsorption from acetone under sealed stirring conditions for 24 hours, followed by solvent evaporation. Characterization via FTIR, CD, SEM, TEM, and nitrogen sorption confirmed successful encapsulation and chiral structural integrity. Differential scanning calorimetry (DSC) and X-ray diffraction (XRD) analyses revealed that most crystalline NMS transitioned to an amorphous phase upon encapsulation, enhancing its solubility.
Notably, FD-MSNs exhibited superior chiral responsiveness and wettability compared to FL-MSNs, as supported by molecular simulation studies. Pharmacokinetic evaluation in vivo demonstrated a substantial enhancement in NMS bioavailability-698.45% for FL-MSNs and 887.03% for FD-MSNs-relative to free drug. Moreover, FD-MSNs significantly outperformed FL-MSNs in anti-inflammatory pharmacodynamic response.
This work demonstrates that nimesulide is used for the preparation of chirality-responsive mesoporous silica nanoparticle delivery systems, offering a novel and effective strategy to improve oral bioavailability and therapeutic performance through molecular-level carrier design.